Despite being the most common vaginal condition,1 BV symptoms are often mistaken for a yeast
infection2
JERSEY CITY, N.J.--(BUSINESS WIRE)--
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™
(clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV). BV
results from an overgrowth of certain bacteria, which upsets the balance of the natural vaginal microbiome
(environment) and can lead to symptoms of odor and discharge.3 BV has also been shown to
disproportionately affect non-Hispanic Black and Mexican American women.4,5
In addition to the physical symptoms,3 BV can also impact a woman’s emotional wellbeing.2
In fact, a 2017 survey among 304 women diagnosed with BV2 found that 79% avoided intimacy with their
partner2 and 68% felt self-conscious because of their condition.2 Most women with symptoms
of BV require treatment.6 Women with recurrent BV have reported frustration with recurrence after
initial treatment,7 with 58% of them experiencing recurrent infection within 12 months.7
XACIATO, pronounced zah-she-AH-toe, is a colorless single-dose vaginal gel that can be applied at any time of
day and is formulated with the goal of limiting leakage and increasing vaginal retention time (time spent in
place).4 As demonstrated by an in vitro study using clindamycin HCl, the gel increases viscosity
(thickness and stickiness) at body temperature and gradually releases clindamycin, over time.4,8
“As a company focused on women's health, we make it a priority to listen to women and their providers, so that
we understand their needs and put forward innovative solutions,” said Juan Camilo Arjona Ferreira, M.D., Head of
Research & Development and Chief Medical Officer at Organon. “What drew us to XACIATO is that it was
formulated with specific needs in mind and studied in a patient population that was representative of women with
BV.”1
XACIATO is contraindicated in individuals with a history of hypersensitivity to clindamycin or lincomycin.
Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all
antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis.
Careful medical history is necessary since CDAD has been reported to occur over 2 months after the
administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not
directed against C. difficile may need to be discontinued.
“BV is the most common form of vaginitis,1,9 disrupting the lives of approximately 21 million
women.1,5 For these women, it’s important to consider her individual treatment needs, such as
route of administration, cost, adverse events, dosing and duration of treatment,”7,10 said Erica
Montes, M.D., Board-Certified Obstetrician and Gynecologist and a Fellow of the American College of OB/GYN. “The
availability of XACIATO is important as it’s one dose for women experiencing BV and it can be taken at any time
of day.”
In 2022, Organon and Daré Bioscience completed an agreement whereby Organon will license global rights to
XACIATO.
Information about XACIATO, and the eVoucher instant savings coupon for eligible patients, can be found at XACIATO.com.
About BV
BV is the most common vaginal condition in women of reproductive age in the United States, affecting
approximately 21 million women.1,5 The condition results from an overgrowth of certain
bacteria, which upsets the balance of the natural vaginal microbiome and can lead to symptoms of odor or
discharge.3 BV may self-resolve in up to 30% of women, but most symptomatic women require
treatment.6,11 If left untreated, BV may lead to serious complications.2,11 BV has also
been shown to disproportionately affect non-Hispanic Black and Mexican American women.4,5
About XACIATO
XACIATO is indicated for the treatment of bacterial vaginosis in females 12 years and older. A single-dose
user-filled disposable applicator delivers 5g of vaginal gel containing 100mg of clindamycin.
Selected Safety Information
XACIATO is contraindicated in individuals with a history of hypersensitivity to clindamycin or lincomycin.
Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all
antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis.
Careful medical history is necessary since CDAD has been reported to occur over 2 months after the
administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not
directed against C. difficile may need to be discontinued.
Polyurethane condoms are not recommended during treatment with XACIATO or for 7 days following treatment. During
this time period, polyurethane condoms may not be reliable for preventing pregnancy or for protecting against
transmission of HIV and other sexually transmitted diseases. Latex or polyisoprene condoms should be used.
XACIATO may result in the overgrowth of Candida spp. in the vagina resulting in vulvovaginal candidiasis,
which may require antifungal treatment.
The most common adverse reactions reported in >2% of patients and at a higher rate in the XACIATO group than
in the placebo group were vulvovaginal candidiasis and vulvovaginal discomfort.
XACIATO has not been studied in pregnant women. However, based on the low systemic absorption of XACIATO
following the intravaginal route of administration in nonpregnant women, maternal use is not likely to result in
significant fetal exposure to the drug.
There are no data on the effect of clindamycin on milk production. The developmental and health benefits of
breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential
adverse effects on the breastfed child from clindamycin or from the underlying maternal condition.
Please see the
Prescribing Information
,
Patient Information
, and
Instructions for Use.
About Organon
Organon is a global healthcare company formed to focus on improving the health of women throughout their lives.
Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars
business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing
products produce strong cash flows that support investments in innovation and future growth opportunities in
women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with
biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in
fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities,
and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.
For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.
Forward-Looking Statements
Some statements and disclosures in this press release are “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited
to, statements regarding product development and commercialization plans for XACIATO. Forward-looking statements
include all statements that do not relate solely to historical or current facts and can be identified by the use
of words such as "may," “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,”
or words of similar meaning. These forward-looking statements are based on our current plans and expectations
and are subject to a number of significant risks and uncertainties. If underlying assumptions prove inaccurate
or risks or uncertainties materialize, actual results may differ materially from the forward-looking statements.
Risks and uncertainties that may affect our future results include, but are not limited to, an inability to
fully execute on the nationwide commercialization plans for XACIATO; our product development and
commercialization plans within the United States or internationally; an inability to adapt to the industry-wide
trend toward highly discounted channels; changes in tax laws or other tax guidance which could adversely affect
our cash tax liability, effective tax rates, and results of operations and lead to greater audit scrutiny; an
inability to execute on our business development strategy or realize the benefits of our planned acquisitions;
efficacy, safety, or other quality concerns with respect to marketed products, including market actions such as
recalls, withdrawals, or declining sales; political and social pressures, or regulatory developments, that
adversely impact demand for, availability of, or patient access to contraception and fertility products; general
economic factors, including recessionary pressures, interest rate and currency exchange rate fluctuations;
general industry conditions and competition; the impact of the ongoing COVID-19 pandemic and emergence of
variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United
States and internationally; global trends toward health care cost containment; technological advances; new
products and patents attained by competitors; challenges inherent in new product development, including
obtaining regulatory approval; the company’s ability to accurately predict its future financial results and
performance; manufacturing difficulties or delays; financial instability of international economies and
sovereign risk; difficulties developing and sustaining relationships with commercial counterparties; dependence
on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise. Additional factors that could cause results to differ materially
from those described in the forward-looking statements can be found in the company’s filings with the Securities
and Exchange Commission ("SEC"), including the company’s Annual Report on Form 10-K for the year ended December
31, 2022 and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).
1 Bacterial vaginosis statistics. Centers for Disease Control and Prevention. Last reviewed February
10, 2020. Accessed October 19, 2023. https://www.cdc.gov/std/bv/stats.htm
2 Understanding women’s experiences with bacterial vaginosis. American Sexual Health Association.
Accessed October 19, 2023. https://www.ashasexualhealth.org/understanding-womens-experiences-with-bacterial-vaginosis/
3 Bacterial vaginosis - CDC basic fact sheet. Centers for Disease Control and Prevention. January 5,
2022. Accessed October 19, 2023. https://www.cdc.gov/std/bv/stdfact-bacterial-vaginosis.htm
4 Mauck C, Hillier SL, Gendreau J, et al. Single-dose bioadhesive clindamycin 2% gel for bacterial
vaginosis. Obstet Gynecol. 2022;00:1–11. DOI: 10.1097/AOG.0000000000004805.
5 Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United
States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis.
2007;34(11):864-9.
6 Bacterial vaginosis. Centers for Disease Control and Prevention. July 19, 2021. Accessed October
19, 2023. https://www.cdc.gov/std/treatment-guidelines/bv.htm
7 Muzny CA, Kardas P. A Narrative Review of Current Challenges in the Diagnosis and Management of
Bacterial Vaginosis. Sex Transm Dis. 2020 Jul;47(7):441-446. doi: 10.1097/OLQ.0000000000001178. PMID: 32235174;
PMCID: PMC7294746.
8 Mondal P, Hemant AH, Johnston TP. Evaluation of TRI-726 as a drug delivery matrix. Drug Dev Ind
Pharm. 2011;37(8):995-1001. doi:10.3109/03639045.2011.555913
9 Paladine HL, Desai UA. Vaginitis: diagnosis and treatment. Am Fam Physician. 2018;97(5):321-329.
10 Chavoustie SE, Eder SE, Koltun WD, et al. Experts explore the state of bacterial vaginosis and the
unmet needs facing women and providers. Int J Gynaecol Obstet. 2017;137(2):107-109.doi: 10.1002/ijgo.12114.
11 Kairys N, Garg M. Bacterial vaginosis. NCBI Bookshelf. Updated July 4, 2023. Accessed October 5,
2023. https://www.ncbi.nlm.nih.gov/books/NBK459216/
Source: Organon & Co.